The Rebound Effect: What Really Happens When You Stop Your Weight Loss Injections ?

For hundreds of thousands of people across the UK, weight loss injections have been genuinely life-changing. The results speak for themselves: significant, sustained weight loss that many patients had previously struggled to achieve through diet and exercise alone. But there is a question that more and more people are beginning to ask — one that deserves an honest, clinically informed answer. What actually happens to your body when you stop?

The short answer is uncomfortable but important: for most people, the weight tends to come back. Not because they have failed, and not because the medication was ineffective — but because of the way these treatments interact with the body's hormonal systems. Understanding this is not a reason to feel disheartened. It is a reason to make informed, personal decisions about your treatment, supported by a regulated healthcare provider you can trust.

What the Latest Research Tells Us

In early 2026, a landmark meta-analysis published in the British Medical Journal (BMJ) provided the most comprehensive picture yet of what happens after people stop weight loss medications. Conducted by researchers at the University of Oxford, the review analysed 37 studies involving 9,341 individuals with excess weight or obesity.

The findings were striking. On average, people lost 14.7 kg while taking newer weight loss medicines such as Wegovy or Mounjaro — impressive results by any measure. But after stopping, participants regained an average of 0.8 kg per month. Based on this trajectory, the researchers predicted that most people would return to their pre-treatment weight within approximately 18 months of stopping.

In contrast, participants who completed behavioural weight-loss programmes without medication lost a more modest 5.1 kg on average — but regained weight more slowly afterwards. This does not mean medication is the wrong choice. It means that the approach to stopping matters enormously, and that ongoing support, whether through continued treatment or a carefully managed transition, is essential to preserving the results you have worked so hard to achieve.

Weight Loss & Regain: A Comparison at a Glance

Sources: BMJ Meta-Analysis (Oxford, 2026); STEP 1 Trial (Wegovy); SURMOUNT-1 Trial (Mounjaro)

Why Does Weight Return After Stopping?

To understand the rebound effect, it helps to understand how these medications work in the first place. Both Mounjaro (tirzepatide) and Wegovy (semaglutide) belong to a class of medications that mimic the body's own gut hormones — specifically GLP-1 and, in the case of Mounjaro, also GIP. These hormones regulate appetite, slow the rate at which the stomach empties, and influence how the brain perceives hunger and fullness.

While you are taking the medication, these hormonal signals are artificially reinforced. You feel less hungry, you feel full sooner, and the urge to eat beyond your energy needs diminishes significantly. When treatment stops, those external signals disappear — and the body's natural hormonal state reasserts itself. For most people, that means returning hunger, returning cravings, and a return to pre-treatment eating patterns, unless significant lifestyle habits have been embedded during treatment.

This is not a personal failing. It is biology. And it is precisely why NICE guidelines recommend that weight loss medications are used alongside meaningful dietary and lifestyle changes — not as standalone solutions. The NHS and NICE are consistent on this point: medication works best as a tool within a broader, supported programme of change.

Who Is Most at Risk of Regaining Weight?

Whilst weight regain after stopping is common for almost everyone, some factors make it more likely — and more rapid. Understanding your personal risk profile is an important part of planning your treatment journey.

Does This Mean You Should Never Stop?

Not necessarily. There are legitimate medical and personal reasons why people may need or choose to stop their weight loss injection — pregnancy planning, side effects, financial circumstances, or simply reaching a point where they feel ready to manage independently. The key is not to stop abruptly and without a plan.

Clinical guidance strongly supports gradual dose reduction rather than sudden cessation, combined with an active transition to sustainable lifestyle habits. Some patients also consider whether continued low-dose maintenance therapy might be appropriate for the longer term — a decision that should always be made in partnership with a qualified clinician.

What Should You Do If You Are Thinking of Stopping?

The most important step is to speak to a clinician before making any changes to your treatment. This is non-negotiable from a safety perspective, and it is one of the standards that sets a properly regulated online pharmacy apart from less scrupulous providers.

•       Do not stop abruptly — discuss a tapering plan with your prescriber

•       Focus on embedding dietary habits during treatment that will support you afterwards

•       Maintain regular physical activity, which helps to preserve lean muscle mass lost during weight loss

•       Continue regular clinical check-ins, even after stopping medication

•       Be aware of the warning signs of rapid weight regain and seek support early

The Bigger Picture: Weight Loss as an Ongoing Journey

The BMJ research, and the clinical consensus that surrounds it, points to something important: obesity is a chronic condition, not an acute one. For many people, long-term management — whether through medication, lifestyle, or a combination of both — is the most effective path to sustained results.

This shift in understanding is reflected in the way the NHS is approaching weight management. The recent NICE guidance on Wegovy for cardiovascular patients, published in April 2026, is a signal that semaglutide is increasingly recognised not just as a weight loss treatment, but as a medicine with broader, long-term health benefits. Read the NICE guidance here.

For patients managing their weight privately through a regulated online pharmacy, the principle is the same: think long-term, stay supported, and never treat stopping as a finish line when it may simply be a transition point.

Blog medically reviewed by : Palvinder Deol, GPhC Registered Pharmacist, 26 May 2026

1. Weight regain following cessation of anti-obesity pharmacotherapy: a systematic review and meta-analysis. BMJ. 2026. University of Oxford.

2. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med.

3. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1).

4. NHS England. Over a million people could be offered Wegovy to cut heart attack and stroke risk on the NHS. April 2026.

5. National Institute for Health and Care Excellence (NICE). Semaglutide for managing overweight and obesity. Technology Appraisal TA875.

6. British Heart Foundation. Weight-loss injections explained. 2026.